Navigation Links
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Date:12/11/2007

detection of new safety findings.

Please see full prescribing information at http://www.soliris.net.

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for Alexion's first product, Soliris, for all patients with PNH and Alexion began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the EC granted marketing approval for Soliris in the European Union for all patients with PNH. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com.

[ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinic
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 28, 2015 Research and Markets ( http://www.researchandmarkets.com/research/64lx2w/north_america_mri ... America MRI Market - Growth, Trends And Forecasts (2014 ... The North American MRI systems market is estimated to ... $1.58 billion by 2020 with a CAGR of 2.9% ... types namely, the open system, closed system and the ...
(Date:5/29/2015)... DUBLIN , May 28, 2015 Research ... of the "North America Open System MRI Market ... report to their offering. The key players ... , Philips Healthcare, Siemens Healthcare and Toshiba Medical Systems ... tool which is replacing CT because of its higher ...
(Date:5/29/2015)... , May 29, 2015  The annual customer satisfaction ... ranks Praxis EMR as #1 across all specialties. Every ... Research LLC conducts a poll of EHR users and ... results.    Praxis EMR topped 348 ... 18 performance based criteria used by Black Book. In ...
Breaking Medicine Technology:North America MRI Market - Growth, Trends And Forecasts 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2Praxis EMR Ranks #1 for Physician Satisfaction in Black Book's 2015 Survey of Solo and Small Practices 2
... RDEA594 Data to Be Presented at the 2008 Annual European Congress of, Rheumatology ... Phase 1 Human Study of RDEA594 Planned in Second Half of ... ... Biosciences, Inc.,(Nasdaq: RDEA ) today announced the identification of its lead development,candidate ...
... filing anticipated in 1Q 2009 -, PRINCETON, ... ) has nominated PSI-7851 as a lead development ... (HCV). PSI-7851 is a proprietary,nucleotide analogue polymerase inhibitor ... Practice (GLP) animal toxicity studies required for,submission of ...
Cached Medicine Technology:Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 2Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 3
(Date:5/29/2015)... 29, 2015 The Recovery Village ... abuse, and co-occurring mental health treatment facility, will ... for the general public on June 1st, and ... Recovery Village at Palmer Lake will offer affordable ... utilizing traditional and evidence-based therapies, in a luxurious ...
(Date:5/29/2015)... Dot Hill can mark one more item off her bucket list: ... retirement community is the oldest woman to have flown at ... great fun!”, she exclaimed. “I’ve always wanted to jump from ... thought this would be ok.” , “We put on nylon coveralls, ... described. “I don’t remember it being noisy, but the wind ...
(Date:5/29/2015)... 29, 2015 On May 21, 2015, Elle ... When You Get Botox ?” reported on the four ... Elle partnered with Google to determine these results and then ... question in California, for example, is how to keep ... search query is what's the appropriate age to start receiving ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and her ... else: God does no wrong. , It’s fitting, then, that ... is titled “God Does No Wrong.” It focuses on what ... tragedy. , “My story has a positive message about ... something productive, something healing,” Howse said. , “God Does No ...
(Date:5/29/2015)... New York, NY (PRWEB) May 29, 2015 ... Pharmaceuticals unit have reached a confidential Risperdal lawsuit ... who allegedly developed gynecomastia due to his use ... the case had been selected for the third ... in a mass tort litigation underway in Pennsylvania’s ...
Breaking Medicine News(10 mins):Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Indoor Skydiving Brings Thrills to Seniors 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Turning grief from a child’s passing into virtue 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3
... a scientist with Lawson Health Research Institute in London, Ontario ... North America and around the world. Matic has been ... gum tissue of cleft palate patients. His research suggests that ... , Matic is a craniofacial/plastic surgeon at London Health Sciences ...
... 750,000, mostly males, are hooked , , MONDAY, May 12 ... young adults are problem gamblers according to researchers at ... , Problem gambling is defined as gambling associated with ... than you intended or stealing money to gamble. , ...
... May 12 OmniSonics Medical,Technologies, Inc., a developer ... of vascular disease, announced today that it has ... SONIC II is a prospective,multi-center U.S. registry study ... undergoing percutaneous mechanical thrombectomy,for acute limb ischemia (ALI). ...
... Naturlose, a natural sugar,approved as a food ingredient in ... of serum glucose that follow consumption of food (1). In,a ... is currently,studying the efficacy and safety of Naturlose for the ... has engaged market,research companies to seek feedback as to the ...
... Reporters/Editors/Producers , RE: American Psychological Association 116th Annual Convention ... Room 162A, Meeting Level 1, Boston Convention and Exhibition ... lap tops and two high-speed printers. We will also ... data transmission and APA staff resources. This room will ...
... Joel Ario today announced that the Insurance Department ... the state to,hear from consumers and other affected ... and Independence Blue Cross, plus related,changes, will impact ... held July 8 in Pittsburgh, July 10 in ...
Cached Medicine News:Health News:Research shows timing improves cleft palate surgery 2Health News:Problem Gambling Common Among Young Adults 2Health News:OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 3Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 2Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 3Health News:Highlights for APA's 116th Annual Convention in Boston, Aug. 14-17 4Health News:Insurance Department to Hold Statewide Meetings on Proposed Consolidation of Independence Blue Cross, Highmark 2
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Plate Reader is an eight channel photometer for the sequential and simultaneous reading of micro-plate strips with 96 wells. High technology, user friendly, powerful and reliable....
TC-98 elisa strip reader. Reads, calculates, and prints results for up to 12 wells in about 30 seconds. Single point calibration. Multi-point calibration....
Stat Fax 2200 Incubator shaker....
Medicine Products: